PREVENTIS - Trademark Details
Status: 686 - Published For Opposition
Serial Number
79302096
Word Mark
PREVENTIS
Status
686 - Published For Opposition
Status Date
2022-01-11
Filing Date
2020-12-04
Mark Drawing
4000 - Standard character mark
Typeset
Published for Opposition Date
2022-01-11
Attorney Name
Law Office Assigned Location Code
N10
Employee Name
BULLOFF, TOBY ELLEN
Statements
Goods and Services
diagnostic and analytical means for medical purposes in particular chemical preparations for use in disease prevention, namely, for detecting and preventing infectious diseases, in particular, infectious diseases caused by viruses, namely, influenza virus, SARS, RSV, infectious diseases caused by bacteria, namely, leptospirosis, Lyme disease, gonorrhea, syphilis, Helicobacter pylori infection, botulism, tetanus, meningitis, pneumonia, endocarditis, Pink eye, erysipelas, necrotizing fasciitis, chlamydia infection, tuberculosis, infectious diseases caused by monocellular organisms, namely, fungi, amoebozoa, entamoebia, dermatophytesm, ringworm, tinea, tinea pedis, oncological diseases, namely, colorectal cancer, cancers of colon, bladder, testicles, prostate, lymphoma, gastroenterological diseases, namely, morbus Crohn, celiac disease, inflammatory bowel syndrome (IBS), inflammatory bowel disease (IBD), diseases and conditions diagnosed by gluten-derived immunogenic peptides (GIP) in stool, urine, diseases of the bones, gastrointestinal diseases increasing the concentration of calprotectin in blood, serum, feces, gastrointestinal syndromes, metabolic diseases, diseases caused by unbalanced vitamin supply and malnutrition, in particular, vitamin D, vitamin B1, vitamin B12, diseases affecting the concentration of the Thyroid-stimulating hormone (TSH), C-reactive protein (CRP), D-Dimer, microalbumin in bodily fluids, urine, and stool, cardiovascular diseases, namely, myocardial infarct, diseases affecting the troponin-level in bodily fluids, conditions affecting women's health, in particular, the concentration of choriogonadotropin, ollicle-stimulating hormone (FSH), luteinizing hormone (LH) in bodily fluids and urine; chemical preparations for use in medical and pharmaceutical detection kits, namely, for detecting infectious diseases, in particular, infectious diseases caused by viruses, namely, influenza virus, SARS, RSV, infectious diseases caused by bacteria, namely, leptospirosis, Lyme disease, gonorrhea, syphilis, Helicobacter pylori infection, botulism, tetanus, meningitis, pneumonia, endocarditis, Pink eye, erysipelas, necrotizing fasciitis, chlamydia infection, tuberculosis, infectious diseases caused by monocellular organisms, namely, fungi, amoebozoa, entamoebia, dermatophytesm, ringworm, tinea, tinea pedis, oncological diseases, namely, colorectal cancer, cancers of colon, bladder, testicles, prostate, lymphoma, gastroenterological diseases, namely, morbus Crohn, celiac disease, inflammatory bowel syndrome (IBS), inflammatory bowel disease (IBD), diseases and conditions diagnosed by gluten-derived immunogenic peptides (GIP) in stool, urine, diseases of the bones, gastrointestinal diseases increasing the concentration of calprotectin in blood, serum, feces, gastrointestinal syndromes, metabolic diseases, diseases caused by unbalanced vitamin supply and malnutrition, in particular, vitamin D, vitamin B1, vitamin B12, diseases affecting the concentration of the Thyroid-stimulating hormone (TSH), C-reactive protein (CRP), D-Dimer, microalbumin in bodily fluids, urine, and stool, cardiovascular diseases, namely, myocardial infarct, diseases affecting the troponin-level in bodily fluids, conditions affecting women's health, in particular, the concentration of choriogonadotropin, ollicle-stimulating hormone (FSH), luteinizing hormone (LH) in bodily fluids and urine; chemicals for medical diagnostics and analysis relating to infectious diseases, in particular, infectious diseases caused by viruses, namely, influenza virus, SARS, RSV, infectious diseases caused by bacteria, namely, leptospirosis, Lyme disease, gonorrhea, syphilis, Helicobacter pylori infection, botulism, tetanus, meningitis, pneumonia, endocarditis, Pink eye, erysipelas, necrotizing fasciitis, chlamydia infection, tuberculosis, infectious diseases caused by monocellular organisms, namely, fungi, amoebozoa, entamoebia, dermatophytesm, ringworm, tinea, tinea pedis, oncological diseases, namely, colorectal cancer, cancers of colon, bladder, testicles, prostate, lymphoma, gastroenterological diseases, namely, morbus Crohn, celiac disease, inflammatory bowel syndrome (IBS), inflammatory bowel disease (IBD), diseases and conditions diagnosed by gluten-derived immunogenic peptides (GIP) in stool, urine, diseases of the bones, gastrointestinal diseases increasing the concentration of calprotectin in blood, serum, feces; gastrointestinal syndromes, metabolic diseases, diseases caused by unbalanced vitamin supply and malnutrition, in particular, vitamin D, vitamin B1, vitamin B12, diseases affecting the concentration of the Thyroid-stimulating hormone (TSH), C-reactive protein (CRP), D-Dimer, microalbumin in bodily fluids, urine, and stool, cardiovascular diseases, namely, myocardial infarct, diseases affecting the troponin-level in bodily fluids, conditions affecting women's health, in particular, the concentration of choriogonadotropin, ollicle-stimulating hormone (FSH), luteinizing hormone (LH) in bodily fluids and urine; all the aforesaid goods not for veterinary use; chemicals for medical diagnostics and analysis in the nature of chemical preparations for rapid testing of infectious diseases caused by viruses, namely, influenza virus, SARS, RSV, infectious diseases caused by bacteria, namely, leptospirosis, Lyme disease, gonorrhea, syphilis, Helicobacter pylori infection, botulism, tetanus, meningitis, pneumonia, endocarditis, Pink eye, erysipelas, necrotizing fasciitis, chlamydia infection, tuberculosis, infectious diseases caused by monocellular organisms, namely, fungi, amoebozoa, entamoebia, dermatophytesm, ringworm, tinea, tinea pedis, oncological diseases, namely, colorectal cancer, cancers of colon, bladder, testicles, prostate, lymphoma, gastroenterological diseases, namely, morbus Crohn, celiac disease, inflammatory bowel syndrome (IBS), inflammatory bowel disease (IBD), diseases and conditions diagnosed by gluten-derived immunogenic peptides (GIP) in stool, urine, diseases of the bones, gastrointestinal diseases increasing the concentration of calprotectin in blood, serum, feces, gastrointestinal syndromes, metabolic diseases, diseases caused by unbalanced vitamin supply and malnutrition, in particular, vitamin D, vitamin B1, vitamin B12, diseases affecting the concentration of the Thyroid-stimulating hormone (TSH), C-reactive protein (CRP), D-Dimer, microalbumin in bodily fluids, urine, and stool, cardiovascular diseases, namely, myocardial infarct, diseases affecting the troponin-level in bodily fluids, conditions affecting women's health, in particular, the concentration of choriogonadotropin, ollicle-stimulating hormone (FSH), luteinizing hormone (LH) in bodily fluids and urine
Goods and Services
Laboratory services; services in the field of medicine and diagnostics; research in the field of medicine and chemical, medical and diagnostic analysis, included in this class
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
005, 006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2021-12-09
Primary Code
005
Current Trademark Owners
Party Name
Party Type
20 - Owner at Publication
Legal Entity Type
99 - Other (aktiengesellschaft).
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Name
Party Type
20 - Owner at Publication
Legal Entity Type
99 - Other (aktiengesellschaft).
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
10 - Original Applicant
Legal Entity Type
99 - Other (aktiengesellschaft).
Address
Please log in with your Justia account to see this address.
Correspondences
Name
Michael T. Smith
Address
Please log in with your Justia account to see this address.
International Registrations
International Registration Number
0832642
International Registration Date
2004-02-27
International Publication Date
2021-01-07
International Renewal Date
2024-02-27
Auto Protection Date
2022-07-07
International Status
001 - Request for extension of protection established
International Status Date
2021-01-07
Priority Claimed In
False
First Refusal In
True
Trademark Events
Event Date | Event Description |
2021-01-07 | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB |
2021-01-19 | LIMITATION FROM ORIGINAL APPLICATION ENTERED |
2021-01-21 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2021-01-26 | APPLICATION FILING RECEIPT MAILED |
2021-05-14 | ASSIGNED TO EXAMINER |
2021-05-19 | NON-FINAL ACTION WRITTEN |
2021-05-20 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
2021-05-21 | REFUSAL PROCESSED BY MPU |
2021-05-21 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
2021-06-13 | REFUSAL PROCESSED BY IB |
2021-11-22 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2021-11-22 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2021-11-22 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2021-12-09 | EXAMINERS AMENDMENT -WRITTEN |
2021-12-09 | EXAMINERS AMENDMENT E-MAILED |
2021-12-09 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
2021-12-09 | EXAMINER'S AMENDMENT ENTERED |
2021-12-09 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2021-12-22 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
2021-12-22 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
2021-12-22 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
2022-01-10 | NOTIFICATION PROCESSED BY IB |
2022-01-11 | PUBLISHED FOR OPPOSITION |
2022-01-11 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |